HPRP-A1
General Information
DCTPep ID DCTPep00858
Peptide Name HPRP-A1
Sequence FKKLKKLFSKLWNWK
Sequence Length 15
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
ACP Tumor active peptide
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
NCI-H460 | Lung large cell carcinoma | IC50=13.3 µM | MTT assay | 24h | 1 |
BGC-823 | Human papillomavirus-related endocervical adenocarcinoma | IC50=14.1 µM | MTT assay | 24h | 1 |
A549 | Lung adenocarcinoma | IC50=14.8 µM | MTT assay | 24h | 1 |
MCF-7 | Invasive breast carcinoma of no special type | IC50=15.7 µM | MTT assay | 24h | 1 |
MDA-MB-231 | Breast adenocarcinoma | IC50=22.9 µM | MTT assay | 24h | 1 |
Hemolytic Activity Human red blood cells: MHC=32 μM, MHC: the minimum hemolytic concentration is the concentration of peptide that results in 10% hemolysis of human red blood cells (hRBCs).
Normal (non-cancerous) Cytotoxicity HUVEC: IC50=24.2 μM
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep00858
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C101H156N24O18
Absent amino acids ACDEGHIMPQRTVY
Theoretical pI 10.70
Acidic residues 0
Basic residues 6
Polar residues 2
Molecular weight (Average) 1994.5
Molecular weight (Monoisotopic) 1993.2
Common amino acids K
Net charge 6
Instability index (II) -6.23
Aliphatic index 78.00
Grand average of hydropathicity (GRAVY) -0.833
Half Life
1.1 hours (mammalian reticulocytes, in vitro).
3 min (yeast, in vivo).
2 min (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 11000
Abs 0.1% (=1 g/l) 5.515
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 30592418
Title Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation
Doi 10.1021/acs.molpharmaceut.8b00854
Year 2019
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available